FDA Issues Guidance on Cancer Clinical Trial Eligibility: Laboratory Values
FDA issues guidance on cancer clinical trial eligibility, recommending evidence-based laboratory criteria to reduce unnecessary exclusions in oncology studies.
FDA Issues Guidance on Cancer Clinical Trial Eligibility: Performance Status
FDA issues new guidance on cancer clinical trial eligibility, recommending broader inclusion of patients with ECOG PS2 and KPS 60–70 performance status.
FDA Issues Guidance on Cancer Clinical Trial Eligibility: Washout Periods and Concomitant Medications
Discover the new FDA guidance on oncology trial eligibility criteria, risk-based washout periods, and concomitant medication management for clinical studies.